Global Trust Asset Management Boosts Bristol Myers Squibb Stake

Institutional investor increases position in pharmaceutical company by nearly 3,000%

Apr. 4, 2026 at 10:27am

Got story updates? Submit your updates here. ›

Global Trust Asset Management LLC significantly increased its stake in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns 27,176 shares of the biopharmaceutical company's stock, up from just 900 shares in the prior quarter, representing a 2,916.2% increase in its position.

Why it matters

This substantial increase in ownership by Global Trust Asset Management suggests the institutional investor sees significant upside potential in Bristol Myers Squibb's stock. As a major pharmaceutical company with a diverse drug portfolio, Bristol Myers Squibb's performance is closely watched by the investment community.

The details

According to the 13F filing, Global Trust Asset Management acquired an additional 26,275 shares of Bristol Myers Squibb during the fourth quarter, bringing its total position to 27,176 shares valued at $1.47 million. This represents a nearly 3,000% increase in the firm's stake in the company compared to the prior quarter.

  • Global Trust Asset Management filed its 13F report for the fourth quarter of 2025 on April 4, 2026.
  • The firm increased its Bristol Myers Squibb position during the three-month period ending December 31, 2025.

The players

Global Trust Asset Management LLC

An institutional investment firm that manages a portfolio of assets for its clients.

Bristol Myers Squibb Company

A major American biopharmaceutical company that develops and markets drugs for various therapeutic areas, including oncology, cardiovascular disease, and immunology.

Got photos? Submit your photos here. ›

The takeaway

Global Trust Asset Management's significant increase in its Bristol Myers Squibb position suggests the firm sees strong growth potential in the pharmaceutical company's stock. As a major institutional investor, Global Trust's actions are closely watched by the broader market and could signal increased investor confidence in Bristol Myers Squibb's future performance.